Idatha Emisha Yomtholampilo Ezigulini Ezinomdlavuza Wama-Gastrointestinal

Ibhalwe ngu umhleli

I-Mirati Therapeutics, Inc., inkampani ye-oncology egxile esigabeni somtholampilo, namuhla imemezele imiphumela emihle evela eqenjini leSigaba 2 socwaningo lwe-KRYSTAL-1 oluhlola i-adagrasib kumthamo we-600mg BID ezigulini ezine-pretreated pancreatic ductal adenocarcinoma nezinye izimila zesisu (GI) ephethe ukuguqulwa kwe-KRASG12C, okuhlanganisa umdlavuza we-biliary tract, i-appendix, ithumbu elincane, i-gastro-esophageal junction, kanye nomminzo. Imiphumela yabonisa ukuthi i-adagrasib ibonise umsebenzi obalulekile womtholampilo kanye nokulawulwa kwezifo okubanzi.

Phrinta Friendly, PDF & Imeyili

Okutholakele (Abstract # 519) kuzokwethulwa namuhla ngo-10:00 am ET ngesikhathi seseshini esheshayo engaqondakali ku-2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.      

UDkt. Tanios S. Bekaii-Saab, umphenyi wocwaningo lwe-KRYSTAL-1, uphawule wathi, “Umdlavuza wamathumbu ungeminye yezinhlobo zomdlavuza ezivame kakhulu futhi usaqhubeka uhlotshaniswa nemiphumela engemihle yokuphila ngaphandle kwentuthuko yakamuva, ikakhulukazi ezigulini ezine-GI tumors ezihlala. Ukushintsha kwe-KRASG12C Idatha entsha yomtholampilo eyethulwe ku-ASCO GI ibonisa ukuthi i-adagrasib, inhibitor ye-KRASG12C, ibonise umsebenzi womtholampilo othembisayo ezigulini ezinomdlavuza we-pancreatic nezinye izimila ze-GI. Lokhu okutholakele kwakhela phezu kwedatha yomtholampilo ebibikiwe ngaphambilini ye-adagrasib kumdlavuza we-colorectal kanye nowe-pancreatic, futhi ikhuthaza kakhulu, iqinisekisa ukuthi kuphenywe okwengeziwe nge-adagrasib kulesi silungiselelo. "

Isifinyezo Semiphumela Yomtholampilo

• Kusukela ngomhla ka-10 Septhemba 2021, ingxenye encane yeziguli ezinomdlavuza we-GI ezifukamele ukuguqulwa kwe-KRASG12C ezibhaliswe ku-adagrasib monotherapy arm (n=30) ithole okungenani imigqa emibili yangaphambili ye-systemic anticancer therapy, futhi yaba nokulandelelwa okumaphakathi kwezinyanga ezingu-6.3 .

• Ezigulini ezihlolwayo (n=27), izinga lokuphendula lenhloso (ORR) lalingu-41% kanti izinga lokulawula isifo (DCR) lalingu-100%. Ezigulini ezihlolwayo ezinomdlavuza we-pancreatic (n = 10), izinga lokuphendula (RR) laliyi-50%, kuhlanganise ne-1 impendulo eyingxenye engaqinisekisiwe (PR); ubude besikhathi sokuphendula (mDOR) bebuyizinyanga ezingu-7.0, nokulandelela okumaphakathi kwezinyanga ezingu-8.1. Ezigulini ezinezinye izimila ze-GI (n = 17), i-RR yayingama-35%, nama-PR amabili angaqinisekisiwe; i-mDOR yayiyizinyanga ezingu-7.9 kulezi ziguli, nokulandelela okumaphakathi kwezinyanga ezingu-6.3.

• I-median progression free survival (mPFS) ezigulini ezinomdlavuza we-pancreatic kwakuyizinyanga ezingu-6.6 (95% Confidence Interval, CI: 1.0, 9.7), futhi ezigulini ezinezinye izimila ze-GI, i-mPFS yayiyizinyanga ezingu-7.9 (95% CI 6.90– 11.30).

• Kulo lonke iqoqo elincane leziguli ezinomdlavuza we-GI oguquliwe we-KRASG12C ohlolwe kuleli qoqo, i-adagrasib yabekezelelwa kahle, nephrofayili yokuphepha elawulekayo. Izehlakalo ezimbi ezihlobene nokwelashwa eziphathelene nokwelashwa (TRAEs) zeBanga lesi-3/4 zabonwa ku-27% weziguli ezalashwa nge-adagrasib, ngaphandle kwama-TRAE aholela ekuyekisweni kokwelashwa, futhi awekho ama-TRAE weBanga lesi-5 aphawuliwe.

"Sikholelwa ukuthi i-adagrasib inephrofayili yamangqamuzana ehlukene, futhi idatha eyethulwa ku-ASCO GI iqhubeka nokusekela iphrofayili yayo engaba ngcono kakhulu ekilasini," kusho uCharles M. Baum, MD, Ph.D., umsunguli, umongameli kanye nenhloko yocwaningo kanye development, Mirati Therapeutics, Inc. “Imiphumela ibonise umsebenzi omuhle womtholampilo ezigulini ezinomdlavuza we-GI oguquliwe we-KRASG12C olashwe nge-agent eyodwa i-adagrasib, ikakhulukazi lezo ezinomdlavuza wamaphakethi lapho izinketho zilinganiselwe. Siyaqhubeka nokuhlola ngamandla i-adagrasib njenge-ejenti eyodwa futhi ngokuhlanganisa neminye imithi yomdlavuza ohlelweni olubanzi lokuthuthukisa ukusiza abantu abaningi abaphila nomdlavuza. "

Phrinta Friendly, PDF & Imeyili

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Shiya amazwana

eTurboNews | I-TravelIndustry News